May 5, 2026 Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 5, 2026 Biomed Industries, Inc. Advances Dual-Track Obesity Therapy Strategy with Near-Term Revenue and NA-931 Phase 3 Launch
